In a Nutshell (TL;DR)
According to studies, 75 to 85% of all menopausal women experience hot flashes, which last for an average of about seven and a half years. They are not "all in your head" but are caused by an estrogen-related dysfunction of the brain's temperature control center.
Hormone therapy (MHT) is the best-supported treatment, followed by the hormone-free drug class Fezolinetant, approved in 2023/2024. Cognitive behavioral therapy, hypnosis, and weight loss also have solid evidence. Conversely, large reviews show no benefit for black cohosh or most "home remedies" compared to a placebo, and even magnesium failed to provide demonstrable relief for hot flashes in the largest study to date.
Important distinction: Hot flashes before the age of 40, accompanied by heart palpitations and weight loss, or occurring with diarrhea and skin flushing, should be medically evaluated, as they may indicate hyperthyroidism or rarer underlying causes.
Important Medical Note
This article provides health information and is not a substitute for a gynecological or primary care examination. Hot flashes before the age of 40, accompanied by unintended weight loss, heart palpitations, diarrhea, or pronounced skin flushing, or new bleeding occurring after menopause, should always be medically evaluated.
Hormone therapy and prescription medications such as Fezolinetant require an individual benefit-risk assessment by a doctor. Dietary supplements are not drugs and do not treat hormonal disorders. Please consult a doctor before taking Ashwagandha if you have existing medical conditions, are pregnant or breastfeeding, or are taking medication (especially thyroid medication, sedatives, or immunosuppressants).
How many women are truly affected?
Hot flashes are among the most common menopausal symptoms: According to the MSD Manual, 75 to 85% of all women transitioning into menopause are affected, lasting for an average of about seven and a half years – and significantly longer for some. The BARMER insurance provider offers a more nuanced assessment: while about three-quarters of women experience hot flashes, only about one-third find them truly distressing.
→ Source: MSD Manual – Menopause, Patient Edition
→ Source: BARMER – Menopause: Sweating & Hot Flashes
Menopause or another cause? Making the important distinction
Not every hot flash is automatically a symptom of menopause. Especially when it occurs well before the age of 40 or is accompanied by atypical symptoms, it is worth looking closely at other potential causes – ranging from hyperthyroidism to medication side effects.
| Potential Cause | Typical Signs | What to do |
|---|---|---|
| Perimenopause / Menopause | Usually begins between ages 45–55, often accompanied by irregular cycles, sleep problems, night sweats | Laboratory diagnostics usually not necessary; see "Diagnostics" section |
| Primary Ovarian Insufficiency | Menopausal symptoms occurring before the age of 40 | Medical evaluation, as early estrogen deficiency carries its own risks |
| Hyperthyroidism | Additionally: heart palpitations, weight loss despite increased appetite, inner restlessness | TSH blood test with your GP |
| Medications | E.g., Tamoxifen and other breast cancer therapies, some antidepressants, opioid withdrawal | Do not stop taking medication without consulting your prescribing physician |
| Rare causes (Carcinoid syndrome, mastocytosis) | Hot flashes combined with diarrhea, abdominal cramps, pronounced skin flushing | Rare, but see a doctor if this specific combination occurs |
This table does not replace a diagnosis. The vast majority of midlife women with hot flashes have a common, yet serious, menopausal symptom – not a warning sign of another underlying disease.
Why do hot flashes occur? The underlying physiology
Declining estrogen levels directly affect the temperature regulation center in the hypothalamus. A frequently cited study by Robert Freedman showed that in women experiencing hot flashes, the so-called "thermoneutral zone" – the temperature range where the body neither sweats nor shivers – is significantly narrowed. Even minimal increases in core body temperature trigger the typical reaction: vasodilation in the skin, a feeling of heat, sweating, and often subsequent shivering.
Research in recent years has decoded exactly what triggers this dysfunction at the cellular level: specific nerve cells in the hypothalamus—called KNDy neurons (named after the messengers kisspeptin, neurokinin B, and dynorphin)—enlarge due to estrogen deficiency and release increased amounts of neurokinin B, which in turn throws the temperature center off balance. This mechanism is not a minor detail: it is the foundation for the new class of medication described in the Fezolinetant section below.
Hormone therapy (MHT): The treatment most effective according to guidelines
The current German S3 guideline "Peri- and Postmenopause – Diagnostics and Interventions" from the German Society of Gynecology and Obstetrics (DGGG) is clear: perimenopausal women with vasomotor symptoms should be offered hormone therapy, provided there are no contraindications. For women with a uterus, combined estrogen-progestogen therapy is used; for women who have had a hysterectomy, estrogen alone is used. Transdermal application methods (patches, gel) are considered to have a lower risk of thrombosis and stroke compared to oral tablets.
→ Source: AWMF – S3 Guideline Peri- and Postmenopause, Diagnostics and Interventions (DGGG)
It is important to note: the risk is dose-dependent and is likely lower in early postmenopause than in late postmenopause – the guideline thus supports the now-established "window of opportunity principle," suggesting that starting therapy earlier is more favorable than starting very late. Nevertheless, hormone therapy is not an automatic solution: if you have a history of breast cancer, unexplained vaginal bleeding, or a history of thrombosis, an individual gynecological assessment is necessary. Since declining estrogen affects areas beyond just hot flashes, it is often worth looking at related topics such as Libido during menopause or muscle maintenance during menopause, which are frequently discussed during MHT consultations.
Fezolinetant (Veoza): The new hormone-free option
As of December 2023, Fezolinetant (brand name Veoza) became the first EU-wide approved active ingredient that specifically targets the KNDy neuron hub described above: it blocks the neurokinin-3 receptor, thereby directly dampening the dysfunction in the temperature center, completely without hormonal activity. Its market launch in Germany took place on February 1, 2024.
→ Source: Deutsche Apotheker Zeitung – Market launch of Fezolinetant on February 1 (2024)
The registration study evaluated by the IQWiG on 381 women for whom hormone therapy was not an option shows specific figures: among 24 out of 100 women taking Fezolinetant, moderate or severe hot flashes ceased after treatment, compared to 10 out of 100 in the placebo group. Sleep disturbances also improved in 51 out of 100 women taking Fezolinetant compared to 28 out of 100 in the placebo group. Serious side effects were similarly rare in both groups (3–4 out of 100).
→ Source: IQWiG – gesundheitsinformation.de: Fezolinetant (Veoza) for hot flashes
Important safety note: In 2025, a new warning for rare but serious liver damage was issued for Fezolinetant – regular liver function monitoring is therefore mandatory before and during intake. Fezolinetant requires a prescription and must be prescribed on an individual basis by a physician.
→ Source: t-online – Fezolinetant: Menopause medication receives new warning (2025)
Other non-hormonal medication options
The 2023 Non-Hormone Therapy Position Statement from the North American Menopause Society (NAMS) summarizes which non-hormonal agents have sufficient study backing: certain SSRI/SNRI antidepressants, gabapentin, and oxybutynin—all used "off-label" for hot flashes, meaning outside their originally approved indication, but based on controlled studies. "Many women cannot or do not want to take hormone therapy for hot flashes for various reasons, but often don't know which non-hormonal options actually work and which don't," explained Dr. Chrisandra Shufelt, who led the creation of the statement, regarding the core idea.
→ Source: The Menopause Society (NAMS) – 2023 Non-Hormone Therapy Position Statement
Behavioral approaches: What NAMS 2023 recommends – and what it does not
In addition to medications, the 2023 NAMS statement also recognizes three non-pharmacological approaches as having sufficient evidence: cognitive behavioral therapy, clinical hypnosis by trained professionals, and weight reduction for those who are overweight. It is surprising what was explicitly not included in the list of recommended measures, even though they appear as standard advice in many guides: cooling techniques, paced respiration, avoiding "trigger" foods, exercise, yoga, mindfulness training, and acupuncture. The committee evaluated the state of research on these measures specifically for hot flashes as insufficient – not because they are harmful, but because controlled studies do not show a consistent effect on the hot flashes themselves.
"The good news for women is that there are many effective options for distressing hot flashes, including several non-hormonal therapies," said Dr. Stephanie Faubion, NAMS medical director and director of the Mayo Clinic Center for Women's Health, in her assessment of the findings.
Phytotherapy: What the research on black cohosh & Co. really shows
Black cohosh (Cimicifuga racemosa) is one of the best-selling herbal remedies for menopausal symptoms – however, the evidence is sobering. A Cochrane review evaluated 16 randomized controlled trials with a total of 2,027 perimenopausal and postmenopausal women and found no significant difference compared to placebo regarding the frequency of hot flashes (mean difference: 0.07 hot flashes per day, 95% confidence interval −0.43 to 0.56). The authors conclude that the current evidence is insufficient to recommend black cohosh for menopausal symptoms.
Soy isoflavones and red clover supplements were also not included in the list of recommended options in the 2023 NAMS statement – their effect on hot flashes is too inconsistent across various studies to justify a clear recommendation.
Magnesium for hot flashes: What the largest study to date shows
Magnesium is broadly cited in many guides as a remedy for menopausal symptoms – however, for hot flashes specifically, the most significant study to date shows a sobering result. In the randomized, placebo-controlled NCCTG-N10C2 study (Alliance for Clinical Trials in Oncology), 267 postmenopausal women with distressing hot flashes received either 800 mg or 1,200 mg of magnesium oxide daily or a placebo. Result: The frequency and severity of hot flashes did not improve more in the magnesium group than with the placebo – while there was more diarrhea with magnesium. The study authors literally conclude that the results do not support the use of magnesium oxide for hot flashes.
Honest assessment: This does not mean that magnesium is useless during menopause – there is other independent evidence for muscle cramps, sleep quality, and general nutrient intake, which is discussed in the VEYT article on nutrients in menopause. However, for the specific symptom of hot flashes, the evidence is currently negative – which is why magnesium is deliberately not promoted as a remedy for hot flashes in this article.
Ashwagandha: A promising but still recent study
The data situation is different for Ashwagandha (Withania somnifera), the nightshade plant traditionally used in Ayurveda. A randomized, placebo-controlled, double-blind study of 60 women between 45 and 55 years of age in perimenopause tested 300 mg of a highly concentrated root extract (KSM-66) twice daily over 56 days. On the Menopause Rating Scale (MRS), which measures psychological, physical, and urogenital symptoms, the total score in the Ashwagandha group fell from 31.37 to 18.53 – compared to barely any change in the placebo group from 30.73 to 30.03 (p<0.0001). Specifically regarding hot flash frequency, the value in the Ashwagandha group decreased from 14.5 to 10.6 episodes, while it went from 14.6 to 14.0 in the placebo group (p<0.001).
Tolerability was good: Only three mild side effects occurred across both groups, 93.3% of the Ashwagandha participants rated tolerability as good to very good, and adherence to the regimen was 100%.
What does not follow from this: This is a single, albeit methodologically sound, study of only 60 women. Ashwagandha is not yet listed in any of the major guidelines (AWMF S3, NAMS 2023) as a recommended option for hot flashes, and the study does not replace hormone therapy or Fezolinetant for severely distressing symptoms. Independent replication studies with larger sample sizes would significantly strengthen the evidence. Furthermore, Ashwagandha is not suitable for use during pregnancy, breastfeeding, or in cases of hyperthyroidism and certain autoimmune diseases without medical consultation. More information on the state of research regarding Ashwagandha can be found in the VEYT article on Ashwagandha for stress and sleep.
Night sweats: The particularly distressing special case
Hot flashes at night – commonly known as night sweats – are among the most frequently searched variations of the topic according to autocomplete data, and for good reason: they directly interrupt sleep, often several times per night, thereby further increasing daytime fatigue, concentration problems, and irritability. The underlying mechanism is the same as during the day, but the consequences compound: sleep deprivation itself can subjectively intensify hot flashes, while recurrent nocturnal episodes further fragment sleep – a cycle that may require treatment in its own right. Anyone additionally suffering from concentration problems can find an in-depth assessment in the VEYT article on brain fog during menopause; concrete sleep hygiene measures are provided in the article on the sleepmaxxing trend.
Popular home remedies checked: What the studies leave open
Vitamin E, evening primrose oil, and acupuncture are among the most frequently recommended "gentle" home remedies for hot flashes. Controlled studies show no benefit over placebo for evening primrose oil. Regarding acupuncture, the research situation is inconsistent: individual studies show small effects, but larger systematic analyses do not consistently confirm these – which is why acupuncture is not among the recommended options in the 2023 NAMS statement either. Cooling measures such as fans, breathable layered clothing, or a cool bedroom provide noticeable everyday relief for individual episodes, but according to the current state of research, they do not demonstrably change the overall frequency of hot flashes.
Evidence map: An overview of approaches to hot flashes
| Approach | For what | Evidence level | What does not follow |
|---|---|---|---|
| Hormone therapy (MHT) | Vasomotor symptoms, many other symptoms | Very well evidenced, AWMF-S3 recommendation | Not suitable for every woman, individual assessment necessary |
| Fezolinetant | Hormone-free alternative for contraindications | RCT evidence, EU-approved since 2023 | Prescription required, liver monitoring necessary |
| SSRI/SNRI, Gabapentin | Non-hormonal alternative | NAMS-2023 recommended (off-label) | Prescription required, potential side effects |
| Cognitive behavioral therapy / Hypnosis | Stress reduction, symptom management | NAMS-2023 recommended | Does not directly alter hormone status |
| Ashwagandha | Hot flash frequency, MRS total score | 1 RCT (n=60), promising, replication pending | No guideline status, no MHT replacement |
| Black cohosh | Traditionally used for menopausal symptoms | Cochrane: no benefit vs. placebo (16 RCT, n=2,027) | No proven effect on hot flashes |
| Magnesium | Often recommended broadly | Largest RCT (n=267): no effect vs. placebo | Not proven specifically for hot flashes |
This overview does not replace individual medical advice and does not claim to be exhaustive.
The VEYT hot flash check: 5 steps in the right order
1. Exclude warning signs. Starting before age 40, heart palpitations and weight loss, or diarrhea with flushing? If so, have it clarified by a doctor first.
2. Honestly assess the burden. Only one-third of affected women perceive hot flashes as highly distressing – this helps determine how intensive treatment should be.
3. Have a medical consultation about MHT and Fezolinetant. For severe distress, these are the most effective options according to research – an individual risk-benefit assessment is part of this.
4. Utilize behavioral components. Cognitive behavioral therapy, clinical hypnosis, or weight reduction are evidence-based additions without medication side effects.
5. Supplement, don't replace: realistically classify nutrients. Ashwagandha has initial promising data, magnesium for this specific symptom does not – neither replaces doctor-prescribed therapy in cases of high distress.
The VEYT products for this article
A product that aligns with the cited research is Ashwagandha. Magnesium is deliberately not shown – although it is part of the VEYT assortment, the largest controlled study to date shows no effect specifically on hot flashes, and this article does not wish to advertise anything that is not supported by the relevant studies.
VEYT Ashwagandha Root Balance
High-dose Ashwagandha capsules. The cited perimenopause study used 2×300 mg of a comparably highly concentrated KSM-66 extract over 56 days – it does not replace doctor-prescribed hormone therapy or Fezolinetant in cases of severe distress, and is not suitable for use during pregnancy/breastfeeding or with hyperthyroidism without medical consultation.
View VEYT Ashwagandha Root Balance →Food supplements are not a substitute for a balanced, varied diet and a healthy lifestyle. The recommended daily intake must not be exceeded. Keep out of reach of small children.
Expert Perspectives & Protocol Breakdown
Dr. Chrisandra Shufelt (Mayo Clinic, Chair of the 2023 NAMS Nonhormone Therapy Position Statement Panel)
Shufelt led the expert panel that, in 2023, conducted the first systematic assessment of which non-hormonal options for hot flashes actually have robust study evidence. Her central message: Many measures recommended in daily life are not inherently wrong, but they are also not supported by controlled studies – this should be communicated transparently during consultations.
Dr. Stephanie Faubion (Mayo Clinic Center for Women's Health, Medical Director of the Menopause Society)
In her interpretation of the NAMS statement, Faubion emphasizes that women today have a wider range of effective options available than they did just a few years ago—both hormonal and non-hormonal—and that the choice should be made individually based on symptom profile, pre-existing conditions, and personal preference.
AWMF/DGGG Guideline Commission (S3 Guideline on Peri- and Postmenopause)
The German Guideline Commission positions hormone therapy as the first-line treatment for vasomotor symptoms in the absence of contraindications, but explicitly points to the dose- and timing-dependent risk profile and recommends individual counseling rather than a blanket recommendation for or against MHT.
Where They Differ
The NAMS position (Shufelt, Faubion) and the German S3 guideline are fundamentally in agreement: Hormone therapy is the most effective single option; non-hormonal alternatives with RCT evidence are a sensible addition for women who cannot or do not want to take hormones. Differences lie in the details of the approval status—Fezolinetant has been available in the EU since late 2023, while individual agents discussed in the USA are not approved in the same form in Germany.
What the Evidence Says
Controlled studies most robustly support hormone therapy and Fezolinetant, followed by cognitive behavioral therapy, hypnosis, and certain antidepressants/gabapentin. For ashwagandha, there is a single, but methodologically sound RCT with a positive result—sufficient for a cautious, supplementary recommendation, but not for equivalence with guideline-recommended therapies. For black cohosh and magnesium specifically regarding hot flashes, the best available evidence currently shows no advantage over placebo.
What should not be labeled as a solution for hot flashes for the time being
"Hot flashes are purely psychological"
Hot flashes have a clearly demonstrable physiological basis in the brain's temperature regulation—they are not imaginary and not merely a stress reaction, even though stress can intensify individual episodes.
"Black cohosh is proven to be effective against hot flashes"
The most comprehensive Cochrane analysis to date (16 studies, over 2,000 women) found no significant difference compared to placebo.
"If you have hot flashes at a young age, you don't need to worry"
The opposite is the case: Hot flashes well before the age of 40 are a reason for medical evaluation, among other things due to potential premature ovarian insufficiency.
"Hormone therapy is dangerous for all women"
This blanket concern stems largely from older, partially misunderstood study data. Current guidelines, such as the German S3 guideline, classify hormone therapy as a safe and effective option when there are no contraindications and after individual assessment, especially when started in early postmenopause.
"Magnesium helps equally well with all menopausal symptoms"
There is independent evidence for sleep, muscle cramps, and general nutritional support—but for hot flashes specifically, the largest study to date shows no effect.
Conclusion
Hot flashes are real, physiologically explainable, and affect most women during menopause—according to study data, the most effective treatments are hormone therapy and the new drug class Fezolinetant, followed by cognitive behavioral therapy, hypnosis, and certain non-hormonal medications. Ashwagandha has initial promising data, but this is not yet supported by guidelines; black cohosh and magnesium have not yet been able to provide proof in controlled studies.
Food supplements are a possible addition, not a treatment for hormonal changes. Anyone suffering from significant strain or noticing warning signs should address this with a doctor rather than relying solely on supplements.
Frequently Asked Questions about hot flashes in menopause
How long do menopausal hot flashes last?
On average, about seven and a half years, and significantly longer for some women—the intensity decreases over time for most women.
What helps fastest against an acute hot flash?
Immediate cooling measures like a fan, cold water on the face, or wearing breathable clothing in layers can alleviate an individual episode, but according to studies, they do not change the overall frequency of hot flashes.
Does black cohosh really help with hot flashes?
The currently most comprehensive Cochrane analysis (16 studies, over 2,000 women) found no significant benefit over placebo.
Is Fezolinetant (Veoza) available in Germany?
Yes, it has been available by prescription since February 1, 2024. Due to a warning issued in 2025 regarding rare liver damage, regular monitoring of liver values is mandatory.
Does magnesium help with hot flashes?
The largest controlled study on this to date (n=267) found no difference compared to placebo. Independent of this, there is evidence for other menopausal symptoms such as sleep and muscle cramps.
Can ashwagandha help with hot flashes?
A single randomized controlled trial of 60 women showed a reduction in the frequency of hot flashes compared to placebo. The data is promising but is not yet supported by guidelines.
When should hot flashes be medically evaluated?
When they start before the age of 40, are accompanied by heart palpitations and weight loss, diarrhea and skin flushing, or if they severely restrict daily life.
Is hormone therapy for hot flashes safe?
According to the current German S3 guideline, yes, provided there are no contraindications and an individual medical assessment is conducted—the risk is dose-dependent and likely lower in early postmenopause than when started late.
Why do hot flashes occur in the first place?
Declining estrogen alters the activity of specific nerve cells (KNDy neurons) in the brain's temperature center, causing even minor temperature fluctuations to trigger an exaggerated reaction involving a feeling of heat and sweating.
References & Scientific Citations
- MSD Manual – Menopause, Patient Version
- BARMER – Menopause: Sweating & Hot Flashes
- Freedman RR – Reduced thermoregulatory null zone in postmenopausal women with hot flashes, Am J Obstet Gynecol (1999)
- Rance NE et al. – Modulation of body temperature and LH secretion by hypothalamic KNDy neurons, Frontiers in Neuroendocrinology (2013)
- AWMF – S3 Guideline on Peri- and Postmenopause, Diagnostics and Interventions (DGGG)
- Deutsche Apotheker Zeitung – Market launch of Fezolinetant on February 1 (2024)
- IQWiG – gesundheitsinformation.de: Fezolinetant (Veoza) for hot flashes
- t-online – Fezolinetant: Menopause medication receives new warning (2025)
- The Menopause Society (NAMS) – 2023 Nonhormone Therapy Position Statement
- EurekAlert – NAMS releases 2023 Nonhormone Therapy Position Statement (Press release)
- Leach MJ, Moore V – Black cohosh (Cimicifuga spp.) for menopausal symptoms, Cochrane Database of Systematic Reviews (2012)
- Alliance for Clinical Trials in Oncology – NCCTG N10C2, magnesium supplements for menopausal hot flashes
- Ashwagandha root extract for menopausal symptoms – RCT, Frontiers in Reproductive Health (2025)
Source Transparency: The listed physicians and professional societies are used as sources of perspective. Statements regarding mechanisms and effectiveness are categorized primarily based on randomized studies, systematic reviews, and established guidelines. Expert opinion, approval status, and clinical evidence of efficacy are not equated. This article was written independently; figures were verified against the linked original sources.
